Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Reviva Pharmaceuticals Holdi / Equity Bottom-Up

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & expects to begin its 2nd in 2025.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & expects to begin its 2nd in 2025.

Reviva Pharmaceuticals Holdi

RVPH: Year-End OLE Update